Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of MSDC-0602 in Type 2 Diabetes
NCT01280695Phase 2Completed
- Sponsor
- Metabolic Solutions Development Company
- Start
- Feb 2011
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azemiglitazone in type 2 diabetes mellitus (T2DM), sponsored by Metabolic Solutions Development Company. Started Feb 2011; status: completed.
02
Drugs
azemiglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01280695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01280695.